docetaxel + prednisone

Docetaxel + prednisone is a combination chemotherapy regimen primarily used for the treatment of metastatic castration-resistant prostate cancer. Docetaxel is a taxane-class small molecule that inhibits microtubule depolymerization, thereby disrupting mitosis and inducing apoptosis in rapidly dividing cancer cells. Prednisone is a synthetic glucocorticoid that exerts anti-inflammatory and immunosuppressive effects; in this context, it also helps to slow the growth of prostate cancer cells by decreasing testosterone production and may reduce some side effects associated with chemotherapy. The combination was the first regimen shown to prolong survival in men with metastatic castration-resistant prostate cancer and remains a standard of care for this indication[2][3][4]. Docetaxel is mainly metabolized by hepatic cytochrome P450 enzymes CYP3A4/5, while prednisone can induce CYP3A4 but does not significantly alter docetaxel pharmacokinetics or toxicity[1]. The primary developer of docetaxel (Taxotere) was Sanofi.

Brand names

Taxotere

Other names

docetaxelprednisone